Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.

@article{Maruyama2011LapatinibEH,
  title={Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.},
  author={Takanori Maruyama and Kousaku Mimura and Shinichiro Izawa and Ayako Inoue and Shugo Shiba and Mitsuaki Watanabe and Yoshihiko Kawaguchi and Masayuki Inoue and Hisashi Nogata and Shingo Inoue and Hideki Fujii and Koji Kono},
  journal={Anticancer research},
  year={2011},
  volume={31 9},
  pages={2999-3005}
}
BACKGROUND Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents. MATERIALS AND METHODS We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin… CONTINUE READING